Ymmunobio
Preclinical-stage biotechnology company (Basel, Switzerland & Princeton, NJ, USA) developing antibody-based therapies for solid tumors. Programs include antibodies directed at CEACAM family and NPTXR, pursued across multiple modalities (antibody-drug conjugates, radiopharmaceuticals for imaging/therapy, bispecific T-cell engagers, and CAR-T). The company advances IND-enabling preclinical studies, collaborates with research institutes and industry partners, and has obtained regulatory milestones including an FDA Orphan Drug Designation for a CEACAM-targeting antibody.
Industries
Nr. of Employees
small (1-50)
Ymmunobio
Gartengasse 12, CH-4125 Riehen, Switzerland; Princeton, NJ, USA
Patents
Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs
US-12098205-B2
View DetailsTherapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs
US-11773169-B2
View DetailsUse of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis
US-8501192-B2
View Details
Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs
US-12098205-B2
View DetailsTherapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs
US-11773169-B2
View DetailsUse of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis
US-8501192-B2
View DetailsProducts
CEACAM1/5-targeting monoclonal antibody (preclinical)
A human(ized) monoclonal antibody targeting CEACAM family antigens with dual mechanism (checkpoint inhibition and immune agonism); advanced in preclinical studies and granted US FDA Orphan Drug Designation for hepatocellular carcinoma.
NPTXR-targeting antibody platform and modality pipeline (preclinical)
A platform focused on antibodies against a tumor‑exclusive receptor (NPTXR) developed for multiple modalities including dual‑payload ADCs, radiopharmaceutical diagnostics/therapeutics, bispecific T‑cell engagers, and a CAR‑T expansion pathway.
CEACAM1/5-targeting monoclonal antibody (preclinical)
A human(ized) monoclonal antibody targeting CEACAM family antigens with dual mechanism (checkpoint inhibition and immune agonism); advanced in preclinical studies and granted US FDA Orphan Drug Designation for hepatocellular carcinoma.
NPTXR-targeting antibody platform and modality pipeline (preclinical)
A platform focused on antibodies against a tumor‑exclusive receptor (NPTXR) developed for multiple modalities including dual‑payload ADCs, radiopharmaceutical diagnostics/therapeutics, bispecific T‑cell engagers, and a CAR‑T expansion pathway.
Expertise Areas
- Antibody therapeutics for solid tumors
- Antibody-drug conjugate development
- Radiopharmaceutical imaging and therapy
- Bispecific T-cell engager development
Key Technologies
- Monoclonal antibody engineering
- Dual‑payload ADC linker–payload architectures
- Radiochemistry for 177Lu and 161Tb
- PET/SPECT imaging and dosimetry
News & Updates
Collaboration with a national research institute supported by an Innosuisse grant to develop a radiopharmaceutical program targeting NPTXR.
Recognition in the Prix Galien USA Awards, placing 3rd in the biotech startup category.
Closed seed funding round raising $1.4M to advance lead antibody programs to IND-enabling studies.
Abstract published in ASCO describing a fully humanized monoclonal antibody against NPTXR as a candidate for ADC design in gastrointestinal and other cancers.
Selected to present preclinical findings on anti-tumor efficacy and immune microenvironment modulation at BIO-Europe Start-up Spotlight.
U.S. FDA granted Orphan Drug Designation for a CEACAM-targeting antibody for treatment of hepatocellular carcinoma.
Collaboration with a national research institute supported by an Innosuisse grant to develop a radiopharmaceutical program targeting NPTXR.
Recognition in the Prix Galien USA Awards, placing 3rd in the biotech startup category.
Closed seed funding round raising $1.4M to advance lead antibody programs to IND-enabling studies.
Abstract published in ASCO describing a fully humanized monoclonal antibody against NPTXR as a candidate for ADC design in gastrointestinal and other cancers.
Selected to present preclinical findings on anti-tumor efficacy and immune microenvironment modulation at BIO-Europe Start-up Spotlight.
U.S. FDA granted Orphan Drug Designation for a CEACAM-targeting antibody for treatment of hepatocellular carcinoma.